Evidence map›Paper›PMID 41158864›Full record

ArticleiScience2025

Human OPN-derived peptide SV prevents BPD model through interacting with KIF5B to repair mitochondrial damage and inhibit apoptosis.

Ru Yan, Honglian Zhang, Pan Zhang, Mingyue Lv, Yuhan Pu, Lihui Yu, Weilai Jin, Le Zhang, Yahui Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ru YanDepartment of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Honglian ZhangDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Pan ZhangDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Mingyue LvDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Yuhan PuDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Lihui YuWuxi Medical College of Jiangnan University, Wuxi, China.
Weilai JinDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Le ZhangDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.
Yahui ZhouDepartment of Neonatology, Affiliated Children's Hospital of Jiangnan University, Wuxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioactive components in breast milk offer a new therapeutic strategy for bronchopulmonary dysplasia (BPD). While osteopontin (OPN) is supplemented in formula to promote neonatal growth, the therapeutic role of its derived peptide, SVVYGLR (SV), in BPD remains unexplored. This study aimed to elucidate SV's therapeutic mechanisms in BPD. The results revealed that SV significantly enhances cell viability, inhibits hyperoxia/LPS-induced apoptosis, and repairs alveolar epithelial injury. Molecularly, SV restores mitochondrial integrity, upregulates the anti-apoptotic protein BCL-2, and downregulates the pro-apoptotic protein Bax.

Indexed as

Cell biologyMolecular biologyMolecular mechanism of gene regulationNatural sciences

Identifiers

PMID41158864
PMCPMC12557493

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.